Stocks and Investing
Stocks and Investing
Tue, August 13, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Paul Choi Maintained (ASND) at Strong Buy with Increased Target to $195 on, Aug 13th, 2024
Paul Choi of Goldman Sachs, Maintained "Ascendis Pharma A/S" (ASND) at Strong Buy with Increased Target from $170 to $195 on, Aug 13th, 2024.
Paul has made no other calls on ASND in the last 4 months.
There are 6 other peers that have a rating on ASND. Out of the 6 peers that are also analyzing ASND, 1 agrees with Paul's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Vikram Purohit of "Morgan Stanley" Maintained at Hold with Increased Target to $140 on, Thursday, May 16th, 2024
These are the ratings of the 5 analyists that currently disagree with Paul
- Yaron Werber of "TD Cowen" Upgraded from Hold to Strong Buy and Increased Target to $175 on, Tuesday, June 25th, 2024
- Alex Thompson of "Stifel" Initiated at Strong Buy and Held Target at $200 on, Friday, May 31st, 2024
- Li Watsek of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $173 on, Wednesday, May 15th, 2024
- Derek Archila of "Wells Fargo" Maintained at Buy with Increased Target to $262 on, Friday, May 3rd, 2024
- Jessica Fye of "JP Morgan" Maintained at Buy with Increased Target to $170 on, Friday, May 3rd, 2024
Contributing Sources